-+ 0.00%
-+ 0.00%
-+ 0.00%

Deutsche Bank Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300

Benzinga·08/26/2026 17:59:18
语音播报
Deutsche Bank analyst David Hoang maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $287 to $300.